MARKET

VNRX

VNRX

Volitionrx
AMEX
1.340
-0.020
-1.47%
Opening 10:08 10/03 EDT
OPEN
1.350
PREV CLOSE
1.360
HIGH
1.360
LOW
1.330
VOLUME
25.52K
TURNOVER
15.62K
52 WEEK HIGH
4.140
52 WEEK LOW
1.310
MARKET CAP
76.78M
P/E (TTM)
-2.3575
1D
5D
1M
3M
1Y
5Y
Maxim Group Maintains Buy on VolitionRX, Lowers Price Target to $5
Maxim Group analyst Jason McCarthy maintains VolitionRX (AMEX:VNRX) with a Buy and lowers the price target from $8 to $5.
Benzinga · 08/23 13:19
BRIEF-Volitionrx Says Board Passed A Resolution To Increase Size Of Board To Nine Members
BRIEF-Volitionrx Says Board Passed A Resolution To Increase Size Of Board To Nine Members
Reuters · 08/16 22:30
Sidoti's August Micro-Cap Virtual Conference
Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 17-18, 2022.
ACCESSWIRE · 08/16 19:00
BRIEF-VolitionRX appoints Mickie Henshall as an independent director
BRIEF-VolitionRX appoints Mickie Henshall as an independent director
Reuters · 08/16 12:14
Volition Appoints Mickie Henshall as an Independent Director
VolitionRx Limited (NYSE: VNRX) ("Volition"), a multi-national epigenetics company, has announced the appointment of Mickie Henshall to its board of directors effective August 15, 2022. Ms. Henshall was also appointed as a member of the Compensation Commit...
PR Newswire · 08/16 12:00
--Aegis Capital Adjusts Price Target on VolitionRX to $6 From $9, Reiterates Buy Rating
--Aegis Capital Adjusts Price Target on VolitionRX to $6 From $9, Reiterates Buy Rating
MT Newswires · 08/15 10:26
VolitionRX reports Q2 results
VolitionRX press release (<span class="ticker-hover...
Seekingalpha · 08/10 20:47
VolitionRx Limited Announces Second Quarter 2022 Financial Results and Business Update
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the second quarter ended June 30, 2022. Volition management will host a conference call tomorrow, August 11 at 8:30 a.m. U.S. Eastern Time to ...
PR Newswire · 08/10 20:10
More
About VNRX
VolitionRx Limited is a multi-national epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop blood tests to help diagnose and monitor a range of diseases, including certain cancers and diseases associated with NETosis, such as sepsis and COVID-19. The Company’s tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluids. Its Nucleosomics technology uses chromosomal structures called nucleosomes as biomarkers in cancer and other diseases. Its key pillars include Nu.Q , Nu.Q NETs, Nu.Q Capture, Nu.Q Discover and Nu.Q Vet. Its Nu.Q family of tests acts as an early warning system by monitoring treatment response, disease progression and remission. Its Nu.Q tests use epigenetic information from tumor cells nucleosomes that helps physicians select the treatment for each patient, monitor their response and disease progression.

Webull offers kinds of VolitionRX Ltd stock information, including AMEX:VNRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VNRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VNRX stock methods without spending real money on the virtual paper trading platform.